Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC

April 24th 2024

Karim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Dr Narayan on the Mechanism of Action of Nadofaragene Firadenovec in NMIBC

April 23rd 2024

Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

April 22nd 2024

The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Dr Tagawa on the Rationale for Investigating First-Line Nivolumab Plus Cisplatin in Urothelial Cancer

April 17th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the rationale for evaluating nivolumab plus cisplatin-based chemotherapy in first-line urothelial cancer.

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024

Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

April 16th 2024

Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

April 12th 2024

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

Dr Efstathiou on the Evolution of Trimodal Therapy in MIBC

April 11th 2024

Jason Efstathiou, MD, DPhil, discusses the utility of trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

April 10th 2024

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Dr Bochner on Bladder-Sparing Regimens in MIBC

April 9th 2024

Bernard H. Bochner, MD, FACS, discusses ongoing studies evaluating the potential bladder-sparing options for patients with muscle-invasive bladder cancer.

Dr Gopal on Treatment Selection in Second-Line R/R mUC

April 8th 2024

Nikhil A. Gopal, MD, discusses treatment selection in second-line relapsed/ refractory metastatic urothelial cancer.

Dr Petrylak on Emerging Therapeutic Targets in Urothelial Cancer

April 4th 2024

Daniel Petrylak, MD, discusses emerging therapeutic targets showing early potential in metastatic urothelial cancer.

Dr Petrylak on Treatment With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

April 4th 2024

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Neoadjuvant and Adjuvant Trials Could Continue to Individualize Treatment in MIBC

April 4th 2024

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

Insights, Innovations, and Challenges Ahead in the Treatment of Urothelial Carcinoma

April 3rd 2024

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Ongoing Research Pushes for Neoadjuvant Alternatives to Chemotherapy in MIBC

April 1st 2024

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Recent FDA Approvals in Advanced Urothelial Carcinoma Propel Treatment Forward

March 31st 2024

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.